Exelixis
EXEL
#1660
Rank
A$15.72 B
Marketcap
$55.07
Share price
1.26%
Change (1 day)
66.79%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.43. In 2022 the company made an earnings per share (EPS) of $0.87 a decrease over its 2021 EPS that were of $1.12.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.43-50.43%
2022$0.87-22.97%
2021$1.12100%
2020$0.56-65.09%
2019$1.61-53.91%
2018$3.49333.96%
2017$0.81-260.61%
2016-$0.50-58.75%
2015-$1.22-42.45%
2014-$2.115.3%
2013-$2.0143.48%
2012-$1.40-264.29%
2011$0.85-165.88%
2010-$1.29-32.54%
2009-$1.91-17.65%
2008-$2.3275.86%
2007-$1.32-25.64%
2006-$1.788.33%
2005-$1.64-42.86%
2004-$2.8730.34%
2003-$2.20-5.23%
2002-$2.32-0.65%
2001-$2.34-51.88%
2000-$4.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.32 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.83 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.77 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.03 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$21.49 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$21.40 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.83 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$15.19-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.28-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA